Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
Departement of Hematology, Inserm U955 Team 09, APHP Hospital Henri Mondor, Créteil, France.
Am J Hematol. 2016 Sep;91(9):923-30. doi: 10.1002/ajh.24451. Epub 2016 Jul 4.
Primary mediastinal B-cell lymphoma (PMBL) is an entity of B-cell lymphoma distinct from the other molecular subtypes of diffuse large B-cell lymphoma (DLBCL). We investigated the prevalence, specificity, and clinical relevance of mutations of XPO1, which encodes a member of the karyopherin-β nuclear transporters, in a large cohort of PMBL. PMBL cases defined histologically or by gene expression profiling (GEP) were sequenced and the XPO1 mutational status was correlated to genetic and clinical characteristics. The XPO1 mutational status was also assessed in DLBCL, Hodgkin lymphoma (HL) and mediastinal gray-zone lymphoma (MGZL).The biological impact of the mutation on Selective Inhibitor of Nuclear Export (SINE) compounds (KPT-185/330) sensitivity was investigated in vitro. XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197). A higher prevalence (50%) of the recurrent codon 571 variant (p.E571K) was observed in GEP-defined PMBL and was associated with shorter PFS. Age, International Prognostic Index and bulky mass were similar in XPO1 mutant and wild-type cases. KPT-185 induced a dose-dependent decrease in cell proliferation and increased cell-death in PMBL cell lines harboring wild type or XPO1 E571K mutant alleles. Experiments in transfected U2OS cells further confirmed that the XPO1 E571K mutation does not have a drastic impact on KPT-330 binding. To conclude the XPO1 E571K mutation represents a genetic hallmark of the PMBL subtype and serves as a new relevant PMBL biomarker. SINE compounds appear active for both mutated and wild-type protein. Am. J. Hematol. 91:923-930, 2016. © 2016 Wiley Periodicals, Inc.
原发性纵隔 B 细胞淋巴瘤(PMBL)是一种独特的 B 细胞淋巴瘤实体,与其他弥漫性大 B 细胞淋巴瘤(DLBCL)的分子亚型不同。我们研究了核输出载体家族成员 XPO1 基因突变在 PMBL 大样本中的流行率、特异性和临床相关性。通过组织学或基因表达谱(GEP)定义的 PMBL 病例进行测序,并将 XPO1 突变状态与遗传和临床特征相关联。还评估了 XPO1 突变在 DLBCL、霍奇金淋巴瘤(HL)和纵隔灰色区淋巴瘤(MGZL)中的状态。在体外研究了突变对选择性核输出抑制剂(SINE)化合物(KPT-185/330)敏感性的生物学影响。XPO1 突变存在于 117 例 PMBL 病例中的 28 例(24%)和 19 例 HL 病例中的 5 例(26%)中,但在 20 例 MGZL 或 197 例 DLBCL 中不存在/罕见。在 GEP 定义的 PMBL 中观察到更常见的重复密码子 571 变体(p.E571K),与较短的 PFS 相关。XPO1 突变和野生型病例的年龄、国际预后指数和肿块大小相似。KPT-185 以剂量依赖性方式降低携带野生型或 XPO1 E571K 突变等位基因的 PMBL 细胞系的细胞增殖并增加细胞死亡。在转染的 U2OS 细胞中的实验进一步证实,XPO1 E571K 突变对 KPT-330 结合没有明显影响。总之,XPO1 E571K 突变代表 PMBL 亚型的遗传特征,并作为新的相关 PMBL 生物标志物。SINE 化合物对突变型和野生型蛋白均有效。Am. J. Hematol. 91:923-930, 2016. © 2016 Wiley Periodicals, Inc.